AML patients harboring NPM1 mutations were generally included in favorable risk subset accordingly to ELN stratification, when concomitantly absent high-risk cytogenetics or FLT3-ITD alteration [39–42]. The gene discussed is FLT3; the disease is acute myeloid leukemia.